Y Intercept Hong Kong Ltd Purchases 85,951 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Y Intercept Hong Kong Ltd raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 245.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 120,958 shares of the biopharmaceutical company's stock after buying an additional 85,951 shares during the period. Y Intercept Hong Kong Ltd's holdings in Amicus Therapeutics were worth $1,139,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in FOLD. Creative Planning boosted its position in Amicus Therapeutics by 79.6% during the third quarter. Creative Planning now owns 52,855 shares of the biopharmaceutical company's stock valued at $564,000 after buying an additional 23,433 shares during the period. Blue Trust Inc. raised its stake in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 2,831 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Amicus Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company's stock worth $115,000 after purchasing an additional 1,884 shares during the period. abrdn plc grew its holdings in Amicus Therapeutics by 9.1% in the third quarter. abrdn plc now owns 1,808,792 shares of the biopharmaceutical company's stock worth $19,318,000 after purchasing an additional 150,179 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Amicus Therapeutics by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 57,044 shares of the biopharmaceutical company's stock worth $609,000 after purchasing an additional 22,244 shares during the period.

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded up $0.30 during mid-day trading on Friday, reaching $9.49. 3,036,949 shares of the company's stock traded hands, compared to its average volume of 2,330,343. Amicus Therapeutics, Inc. has a 12 month low of $8.78 and a 12 month high of $13.60. The firm has a 50 day moving average price of $9.50 and a two-hundred day moving average price of $10.34. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The firm has a market capitalization of $2.92 billion, a PE ratio of -52.72, a price-to-earnings-growth ratio of 1.51 and a beta of 0.61.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at $8,884,273.08. The trade was a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.20% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on FOLD shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Morgan Stanley reiterated an "equal weight" rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. JPMorgan Chase & Co. increased their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Finally, Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.